<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101186374</journal-id>
<journal-id journal-id-type="pubmed-jr-id">31761</journal-id>
<journal-id journal-id-type="nlm-ta">Nat Struct Mol Biol</journal-id>
<journal-id journal-id-type="iso-abbrev">Nat. Struct. Mol. Biol.</journal-id>
<journal-title-group>
<journal-title>Nature structural &amp; molecular biology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1545-9993</issn>
<issn pub-type="epub">1545-9985</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31582846</article-id>
<article-id pub-id-type="pmc">6951022</article-id>
<article-id pub-id-type="doi">10.1038/s41594-019-0298-7</article-id>
<article-id pub-id-type="manuscript">NIHMS1066370</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Histone lysine methyltransferases in biology and disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Husmann</surname>
<given-names>Dylan</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gozani</surname>
<given-names>Or</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1365-4463</contrib-id>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<aff id="A1">Department of Biology, Stanford University, Stanford, CA, USA.</aff>
</contrib-group>
<author-notes>
<corresp id="CR1"><label>*</label><bold>Correspondence</bold> should be addressed to O.G., <email>ogozani@stanford.edu</email></corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P32">Competing interests</p>
<p id="P33">O.G. is a cofounder of Epicypher, Inc., and Athelas Therapeutics, Inc.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>5</day>
<month>1</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>03</day>
<month>10</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>10</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>03</day>
<month>4</month>
<year>2020</year>
</pub-date>
<volume>26</volume>
<issue>10</issue>
<fpage>880</fpage>
<lpage>889</lpage>
<!--elocation-id from pubmed: 10.1038/s41594-019-0298-7-->
<permissions>
<license license-type="permissions-link">
<license-p><bold>Reprints and permissions information</bold> is available at <ext-link ext-link-type="uri" xlink:href="http://www.nature.com/reprints">www.nature.com/reprints</ext-link>.</license-p>
</license>
</permissions>
<abstract id="ABS1">
<p id="P1">The precise temporal and spatial coordination of histone lysine methylation dynamics across the epigenome regulates virtually all DNA-templated processes. A large number of histone lysine methyltransferase (KMT) enzymes catalyze the various lysine methylation events decorating the core histone proteins. Mutations, genetic translocations and altered gene expression involving these KMTs are frequently observed in cancer, developmental disorders and other pathologies. Therapeutic compounds targeting specific KMTs are currently being tested in the clinic, although overall drug discovery in the field is relatively under-developed. Here we review the biochemical and biological activities of histone KMTs and their connections to human diseases, focusing on cancer. We also discuss the scientific and clinical challenges and opportunities in studying KMTs.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>